Research Article

Efficacy and Safety of Aflibercept Treatment in Patients with Metastatic Colorectal Cancer: A Single-Center Experience

Volume: 52 January 26, 2026
TR EN

Efficacy and Safety of Aflibercept Treatment in Patients with Metastatic Colorectal Cancer: A Single-Center Experience

Abstract

Colorectal cancer is one of the most common malignancies worldwide, and new treatment options are continually emerging. This study aimed to assess the effects and side effects of aflibercept, one of the current treatment options for the condition. We included fifty-two patients diagnosed with colorectal cancer at the Bursa Uludağ University Medical Oncology Department between January 2014 and December 2020. These patients either presented with metastasis at the time of diagnosis or developed it during follow-up and were subsequently treated with aflibercept. Two patients were excluded from the study due to irregular follow-up. Among the patients included, 74% had metastatic disease at diagnosis, and 70% had tumors located in the left colon. KRAS mutations were identified in 56% of the patients. Aflibercept was the most commonly preferred second-line treatment. The median progression-free survival (PFS) after treatment with aflibercept was 5.13 months, while the median overall survival (OS) was 11.9 months. No significant difference was observed in overall survival between patients receiving aflibercept as second-line treatment and those receiving it as later lines. The frequency of side effects was consistent with existing literature; notably, significant proteinuria was observed during treatment.

Keywords

References

  1. 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
  2. 2. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64.
  3. 3. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
  4. 4. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1).
  5. 5. Van Cutsem E, Cervantes A, Nordlinger B, et al. The ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(September):iii1–9.
  6. 6. Patel A, Sun W. Ziv-afibercept in metastatic colorectal cancer. Biol Targets Ther. 2013;8:13–25.
  7. 7. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–85.
  8. 8. Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res. 2013;19(8):1920/5

Details

Primary Language

English

Subjects

​Internal Diseases

Journal Section

Research Article

Publication Date

January 26, 2026

Submission Date

September 1, 2025

Acceptance Date

January 3, 2026

Published in Issue

Year 2026 Volume: 52

APA
Ada, G., Çubukçu, E., & Şahin, A. B. (2026). Efficacy and Safety of Aflibercept Treatment in Patients with Metastatic Colorectal Cancer: A Single-Center Experience. Journal of Uludağ University Medical Faculty, 52, 1776017. https://doi.org/10.32708/uutfd.1776017
AMA
1.Ada G, Çubukçu E, Şahin AB. Efficacy and Safety of Aflibercept Treatment in Patients with Metastatic Colorectal Cancer: A Single-Center Experience. Journal of Uludağ University Medical Faculty. 2026;52:1776017. doi:10.32708/uutfd.1776017
Chicago
Ada, Gül, Erdem Çubukçu, and Ahmet Bilgehan Şahin. 2026. “Efficacy and Safety of Aflibercept Treatment in Patients With Metastatic Colorectal Cancer: A Single-Center Experience”. Journal of Uludağ University Medical Faculty 52 (January): 1776017. https://doi.org/10.32708/uutfd.1776017.
EndNote
Ada G, Çubukçu E, Şahin AB (January 1, 2026) Efficacy and Safety of Aflibercept Treatment in Patients with Metastatic Colorectal Cancer: A Single-Center Experience. Journal of Uludağ University Medical Faculty 52 1776017.
IEEE
[1]G. Ada, E. Çubukçu, and A. B. Şahin, “Efficacy and Safety of Aflibercept Treatment in Patients with Metastatic Colorectal Cancer: A Single-Center Experience”, Journal of Uludağ University Medical Faculty, vol. 52, p. 1776017, Jan. 2026, doi: 10.32708/uutfd.1776017.
ISNAD
Ada, Gül - Çubukçu, Erdem - Şahin, Ahmet Bilgehan. “Efficacy and Safety of Aflibercept Treatment in Patients With Metastatic Colorectal Cancer: A Single-Center Experience”. Journal of Uludağ University Medical Faculty 52 (January 1, 2026): 1776017. https://doi.org/10.32708/uutfd.1776017.
JAMA
1.Ada G, Çubukçu E, Şahin AB. Efficacy and Safety of Aflibercept Treatment in Patients with Metastatic Colorectal Cancer: A Single-Center Experience. Journal of Uludağ University Medical Faculty. 2026;52:1776017.
MLA
Ada, Gül, et al. “Efficacy and Safety of Aflibercept Treatment in Patients With Metastatic Colorectal Cancer: A Single-Center Experience”. Journal of Uludağ University Medical Faculty, vol. 52, Jan. 2026, p. 1776017, doi:10.32708/uutfd.1776017.
Vancouver
1.Gül Ada, Erdem Çubukçu, Ahmet Bilgehan Şahin. Efficacy and Safety of Aflibercept Treatment in Patients with Metastatic Colorectal Cancer: A Single-Center Experience. Journal of Uludağ University Medical Faculty. 2026 Jan. 1;52:1776017. doi:10.32708/uutfd.1776017

ISSN: 1300-414X, e-ISSN: 2645-9027

Creative Commons License
Journal of Uludag University Medical Faculty is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2023